Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Kathleen Vazzana¹, Ankana Daga², Beatrice Goilav³, Ekemini Ogbu⁴, Daryl Okamura⁵, Catherine Park⁶, Rebecca Sadun⁷, Emily Smitherman⁸, Brian Stotter⁹, Scott Wenderfer¹⁰ and Laura Lewandowski¹¹, ¹National Institute of Health/Children's National Hospital, Washington, DC, ²Harvard, Boston, MA, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Seattle's Children's, Seattle, WA, ⁶Emory University, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Washington University School of Medicine, St. Louis, MO, ¹⁰Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹¹NIAMS, NIH, Rockville, MD
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
Abstract Number: 1777 • ACR Convergence 2020
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known…
Abstract Number: 1803 • ACR Convergence 2020
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients
Melissa Munroe¹, Wade DeJager², Susan Macwana², Ly Tran², Joel Guthridge², Eldon Jupe³, Daniele DeFreese³, Ryan Newhardt³, Mohan Purushothaman³, Sanjiv Sharma³, Nancy Redinger², Teresa Aberle², Stan Kamp², Cristina Arriens², Eliza Chakravarty², Joan Merrill⁴ and Judith James⁵, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven by complex immune dysregulation, involving altered immune mediators and accumulation of autoantibody (AutoAb) specificities.…
Abstract Number: 1820 • ACR Convergence 2020
Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity
Margaret Markiewicz¹, Dayvia Russell² and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, Charleston, SC, ².Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
Abstract Number: 1837 • ACR Convergence 2020
Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort
Michelle Petri¹, Qinggong Fu², Yulia Green³, Anuradha Madan⁴, Daniel Goldman⁵ and Selin Cooper-Blenkinsopp⁶, ¹Johns Hopkins University School of Medicine, Baltimore, ²GlaxoSmithKline, Upper Providence, ³GlaxoSmithKline, Uxbridge, ⁴GlaxoSmithKline, Collegeville, ⁵Johns Hopkins University School of Medicine, Timonium, MD, ⁶GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: A retrospective analysis of the Hopkins Lupus Cohort (a prospective, longitudinal study of patients [pts] with systemic lupus erythematosus) reported that renal response (complete/partial/none)…
Abstract Number: 1989 • ACR Convergence 2020
NXP2 Autoantibodies Link to Interferon Signature in Juvenile Myositis Lesional Skin
Jessica Turnier¹, Lauren Pachman², Lori Lowe³, Alex Tsoi³, Sultan Elhaj¹, Rajasree Menon¹, Maria Amoruso², Gabrielle Morgan⁴, Johann Gudjonsson⁵, Celine Berthier³ and J Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Michigan, Ann Arbor, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Michigan, Ann ArborUniversity of Michigan
Background/Purpose: Skin inflammation can herald systemic disease in juvenile myositis (JM), yet we lack an understanding of pathogenic mechanisms driving skin inflammation in JM. The…
Abstract Number: 0087 • ACR Convergence 2020
Hemophagocytic Syndrome. Clinical Characteristics and Prognostic Factors of a Series of 30 Clinical Cases
César Antonio Egües Dubuc¹, Jaime Calvo-Alén², Andrea de Diego Sola³, Elizabeth Patricia Cabrera-Miranda⁴, Nerea Alcorta⁵, Luis Lopez Dominguez⁶, Olga Maiz⁵, Esther Uriarte Isacelaya⁶, Jorge Cancio Fanlo⁷, Jesus Alejandro Valero Jaimes⁶ and Joaquín Belzunegui¹, ¹Hospital Universitario Donostia, San Sebastián, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Hospital Universitario Donostia, San Sebasti�n, Spain, ⁴Hospital 12 de Octubre, Madrid, ⁵Hospital Universitario Donostia, San Sebastian, ⁶Hospital Universitario Donostia, SAN SEBASTIAN, Spain, ⁷Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain
Background/Purpose: Hemophagocytic syndrome (HPS) is classified into primary and secondary. The secondary form is mainly associated with hematological malignancies (HN) such as lymphomas, and autoimmune…
Abstract Number: 0257 • ACR Convergence 2020
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
Milena Gianfrancesco¹, Suzanne Tamang², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Stanford Center for Population Health Sciences, Redwood City, CA, ³University of California, San Francisco, Atherton, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is a frequent complication of SLE and associated with higher morbidity and mortality. Accurate estimates of the prevalence of LN in…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0292 • ACR Convergence 2020
Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
Samantha Slight-Webb¹, Miles Smith², Kevin Thomas¹, Susan Macwana¹, Holden Maecker³, Paul Utz⁴, Judith James⁵ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periods of elevated and suppressed clinical symptoms. Specific cell subsets, such as CD11c+ age-associated…
Abstract Number: 0436 • ACR Convergence 2020
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, Sanjyot Sangodkar², Kathleen Arntsen³, Sang-Cheol Bae⁴, Lauren Bloch², Ian Bruce⁵, Erin Connolly-Strong⁶, Karen Costenbader⁷, Thomas Dörner⁸, Sydney Evans⁹, Timothy Franson², Kenneth Getz¹⁰, Amy Kao¹¹, Kenneth Kalunian¹², Bradley Dickerson¹³, Susan Manzi¹⁴, Eric Morand¹⁵, Yaritza Peña¹⁰, Sandra Raymond¹⁶, Brad Rovin¹⁷, Laura Schanberg¹⁸, Joan Von Feldt¹⁹, Victoria Werth²⁰, Angel Williams²¹, David Zook² and Leslie Hanrahan¹⁶, ¹Lupus Foundation of America, DC, WA, ²Faegre Drinker Consulting, Washington, DC, ³Lupus and Allied Diseases Association, Inc., Verona, NY, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Mallinckrodt, Austin, TX, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸DRFZ and Charité University Hospitals, Berlin, Germany, ⁹Lupus Patient Representative, Riverdale, MD, ¹⁰Tufts Center for the Study of Drug Development, Boston, MA, ¹¹EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹²University of California San Diego, La Jolla, CA, ¹³Aurinia Pharmaceuticals, Fort Washington, PA, ¹⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹⁶Lupus Foundation of America, Washington, DC, ¹⁷The Ohio State University, Columbus, ¹⁸Duke University Medical Center, Durham, NC, ¹⁹GlaxoSmithKline, WILMINGTON, DE, ²⁰University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²¹Lupus Patient Representative, Richmond, VA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…
Abstract Number: 0574 • ACR Convergence 2020
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Katherine Pryor¹, Chang Xu¹, Jamie Collins¹, Karen Costenbader² and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
Abstract Number: 0840 • ACR Convergence 2020
Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation
Samantha Chalmers¹, Sayra Garcia¹, Leal Herlitz², Jeanette Ampudia³, Cherie Ng⁴, Stephen Connelly³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Equillium, Inc, San Diego, CA, ⁴Equillium, Inc, La Jolla, CA
Background/Purpose: CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen-presenting…
Abstract Number: 0858 • ACR Convergence 2020
Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus
Irene Carrión-Barberà¹, Tarek Carlos Salman Monte¹, Luciano Polino¹, Miguel Mejía¹, Manel Ciria¹, Carolina Pérez-García¹, Eva Rodríguez¹ and Jordi Monfort¹, ¹Hospital del Mar, Barcelona, Spain
Background/Purpose: Leflunomide (LEF) is a DMARD commonly used safely and effectively in rheumatoid arthritis. The experience with LEF in SLE is mainly based on what…
Abstract Number: 0946 • ACR Convergence 2020
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun² and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].